Lisata Therapeutics (LSTA) Competitors

$3.31 +0.05 (+1.53%)

As of 02:58 PM Eastern

LSTA vs. RANI, KLRS, BMEA, CRDF, and TTRX

Should you buy Lisata Therapeutics stock or one of its competitors? MarketBeat compares Lisata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lisata Therapeutics include Rani Therapeutics (RANI), Kalaris Therapeutics (KLRS), Biomea Fusion (BMEA), Cardiff Oncology (CRDF), and Turn Therapeutics (TTRX). These companies are all part of the "pharmaceutical products" industry.

How does Lisata Therapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Lisata Therapeutics has lower revenue, but higher earnings than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	83.85	-$29.67M	-$0.59	N/A
Lisata Therapeutics	$170K	177.38	-$16.59M	-$1.91	N/A

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 26.5% of Rani Therapeutics shares are owned by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rani Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Lisata Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Lisata Therapeutics' return on equity of -85.50% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-774.04%	-106.02%
Lisata Therapeutics	N/A	-85.50%	-70.85%

In the previous week, Rani Therapeutics had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 5 mentions for Rani Therapeutics and 3 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.41 beat Rani Therapeutics' score of 0.37 indicating that Lisata Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rani Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lisata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rani Therapeutics presently has a consensus price target of $7.80, indicating a potential upside of 605.88%. Lisata Therapeutics has a consensus price target of $15.00, indicating a potential upside of 353.17%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Rani Therapeutics is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Lisata Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Rani Therapeutics beats Lisata Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to Kalaris Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Lisata Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 353.17%. Kalaris Therapeutics has a consensus target price of $14.00, suggesting a potential upside of 193.56%. Given Lisata Therapeutics' higher probable upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Kalaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Lisata Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	177.38	-$16.59M	-$1.91	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$4.21	N/A

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lisata Therapeutics and Lisata Therapeutics both had 3 articles in the media. Kalaris Therapeutics' average media sentiment score of 1.89 beat Lisata Therapeutics' score of 1.41 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kalaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Kalaris Therapeutics' return on equity of -73.11% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-85.50%	-70.85%
Kalaris Therapeutics	N/A	-73.11%	-43.56%

Lisata Therapeutics has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Kalaris Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market.

Summary

Kalaris Therapeutics beats Lisata Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Lisata Therapeutics compare to Biomea Fusion?

Lisata Therapeutics (NASDAQ:LSTA) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 353.17%. Biomea Fusion has a consensus target price of $8.29, indicating a potential upside of 429.44%. Given Biomea Fusion's stronger consensus rating and higher possible upside, analysts clearly believe Biomea Fusion is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biomea Fusion	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Lisata Therapeutics has higher revenue and earnings than Biomea Fusion. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	177.38	-$16.59M	-$1.91	N/A
Biomea Fusion	N/A	N/A	-$61.80M	-$1.31	N/A

Lisata Therapeutics has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, Biomea Fusion has a beta of -0.32, indicating that its stock price is 132% less volatile than the broader market.

In the previous week, Biomea Fusion had 4 more articles in the media than Lisata Therapeutics. MarketBeat recorded 7 mentions for Biomea Fusion and 3 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 1.41 beat Biomea Fusion's score of 0.79 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biomea Fusion	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lisata Therapeutics' return on equity of -85.50% beat Biomea Fusion's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-85.50%	-70.85%
Biomea Fusion	N/A	-305.60%	-128.09%

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by company insiders. Comparatively, 18.4% of Biomea Fusion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Biomea Fusion beats Lisata Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Lisata Therapeutics compare to Cardiff Oncology?

Lisata Therapeutics (NASDAQ:LSTA) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Lisata Therapeutics has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	177.38	-$16.59M	-$1.91	N/A
Cardiff Oncology	$590K	192.94	-$45.85M	-$0.69	N/A

8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 7.7% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 353.17%. Cardiff Oncology has a consensus target price of $10.10, indicating a potential upside of 506.61%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Lisata Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardiff Oncology	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Lisata Therapeutics had 1 more articles in the media than Cardiff Oncology. MarketBeat recorded 3 mentions for Lisata Therapeutics and 2 mentions for Cardiff Oncology. Lisata Therapeutics' average media sentiment score of 1.41 beat Cardiff Oncology's score of 0.94 indicating that Lisata Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lisata Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiff Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Cardiff Oncology has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

Lisata Therapeutics has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,733.22%. Cardiff Oncology's return on equity of -82.01% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-85.50%	-70.85%
Cardiff Oncology	-7,733.22%	-82.01%	-64.09%

Summary

Cardiff Oncology beats Lisata Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Lisata Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

8.9% of Lisata Therapeutics shares are held by institutional investors. 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Lisata Therapeutics had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 3 mentions for Lisata Therapeutics and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 1.47 beat Lisata Therapeutics' score of 1.41 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Turn Therapeutics	Positive
Lisata Therapeutics	Positive

Turn Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 104.34%. Lisata Therapeutics has a consensus target price of $15.00, indicating a potential upside of 353.17%. Given Lisata Therapeutics' higher possible upside, analysts plainly believe Lisata Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lisata Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Turn Therapeutics' return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Lisata Therapeutics	N/A	-85.50%	-70.85%

Turn Therapeutics has higher earnings, but lower revenue than Lisata Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Lisata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.16	N/A
Lisata Therapeutics	$170K	177.38	-$16.59M	-$1.91	N/A

Summary

Lisata Therapeutics beats Turn Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Lisata Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LSTA vs. The Competition

Export

Metric	Lisata Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.15M	$3.41B	$6.27B	$12.13B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-1.73	15.30	20.53	25.45
Price / Sales	177.38	302.57	545.62	75.37
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	1.99	6.81	9.60	6.64
Net Income	-$16.59M	$24.11M	$3.55B	$333.40M
7 Day Performance	1.22%	-1.67%	-0.34%	-0.45%
1 Month Performance	-33.93%	3.64%	6.09%	7.83%
1 Year Performance	48.36%	70.97%	38.53%	35.63%

Lisata Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LSTA Lisata Therapeutics	2.1388 of 5 stars	$3.31 +1.5%	$15.00 +353.2%	+55.2%	$30.15M	$170K	N/A	30	Positive News Earnings Report Upcoming Earnings
RANI Rani Therapeutics	2.8106 of 5 stars	$0.96 +8.6%	$7.80 +712.4%	+46.6%	$118.76M	$1.63M	N/A	110	News Coverage Upcoming Earnings Analyst Downgrade
KLRS Kalaris Therapeutics	3.4514 of 5 stars	$5.06 -4.5%	$14.00 +176.7%	N/A	$116.33M	N/A	N/A	110	News Coverage Positive News Earnings Report
BMEA Biomea Fusion	2.7759 of 5 stars	$1.60 +5.3%	$8.29 +417.9%	-3.5%	$115.68M	N/A	N/A	50	Earnings Report
CRDF Cardiff Oncology	1.7319 of 5 stars	$1.68 +4.3%	$10.10 +501.2%	-38.7%	$114.86M	$590K	N/A	20	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LSTA) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lisata Therapeutics (LSTA) Competitors

LSTA vs. RANI, KLRS, BMEA, CRDF, and TTRX

How does Lisata Therapeutics compare to Rani Therapeutics?

Summary

How does Lisata Therapeutics compare to Kalaris Therapeutics?

Summary

How does Lisata Therapeutics compare to Biomea Fusion?

Summary

How does Lisata Therapeutics compare to Cardiff Oncology?

Summary

How does Lisata Therapeutics compare to Turn Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lisata Therapeutics (LSTA) Competitors

LSTA vs. RANI, KLRS, BMEA, CRDF, and TTRX

How does Lisata Therapeutics compare to Rani Therapeutics?

Which has preferable valuation & earnings, RANI or LSTA?

Do institutionals & insiders believe in RANI or LSTA?

Which has more volatility & risk, RANI or LSTA?

Is RANI or LSTA more profitable?

Does the media prefer RANI or LSTA?

Do analysts prefer RANI or LSTA?

Summary

How does Lisata Therapeutics compare to Kalaris Therapeutics?

Do analysts recommend LSTA or KLRS?

Which has preferable earnings & valuation, LSTA or KLRS?

Do institutionals & insiders hold more shares of LSTA or KLRS?

Does the media favor LSTA or KLRS?

Is LSTA or KLRS more profitable?

Which has more risk and volatility, LSTA or KLRS?

Summary

How does Lisata Therapeutics compare to Biomea Fusion?

Do analysts prefer LSTA or BMEA?

Which has better earnings and valuation, LSTA or BMEA?

Which has more volatility and risk, LSTA or BMEA?

Does the media prefer LSTA or BMEA?

Is LSTA or BMEA more profitable?

Do institutionals and insiders believe in LSTA or BMEA?

Summary

How does Lisata Therapeutics compare to Cardiff Oncology?

Which has preferable earnings & valuation, LSTA or CRDF?

Do insiders & institutionals believe in LSTA or CRDF?

Do analysts prefer LSTA or CRDF?

Does the media favor LSTA or CRDF?

Which has more risk and volatility, LSTA or CRDF?

Is LSTA or CRDF more profitable?

Summary

How does Lisata Therapeutics compare to Turn Therapeutics?

Do insiders and institutionals believe in TTRX or LSTA?

Does the media refer more to TTRX or LSTA?

Do analysts recommend TTRX or LSTA?

Is TTRX or LSTA more profitable?

Which has stronger valuation and earnings, TTRX or LSTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA vs. The Competition

Lisata Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools